Table 4

Summary of meta-analysis results in the achievement of the virological outcome by Pegylated interferon α-2a and α-2b plus ribavirin in patients with genotype 1 chronic hepatitis C
Outcomes N° of studies N° of patients N° and (%) of events RR (efficacy) 95% CI (efficacy) p Heterogeneity test
α-2a/α-2b α-2a/α-2b (Q;p;I2,%)
Rapid Virological Response 4 [17-19,22] 1,374/1,355 186(13.5)/174(12.8) 1.05 0.87–1.27 0.62 3.8;0.28;21.1
Early Virological Response 5[17-19,21,22] 1,395/1,371 649(46.5)/572(38.4) 1.12 1.03–1.22 0.011 7.58;0.14;42.8
End of Treatment Response 5[16,18,19,21,22] 1,243/1,217 782(62.9)/627(51.5) 1.22 1.14–1.31 <0.0001 7.6;0.11;47.3
5*[16,18,19,21,22] 921/879 544(59)/403(45.8) 1.29 1.18–1.41 <0.0001 8.37;0.08;52.1
Sustained Virological Response 6[16,18-22] 1,336/1,310 574(43)/521(39.8) 1.08 0.99–1.18 0.098 9.97;0.08;49.8
6**[16,18-22] 1,058/732 473(44.7)/306(41.8) 1.08 0.97–1.20 0.19 10.9;0.053;54.2
6*[16,18-22] 1,014/972 406(40)/346(35.5) 1.13 1.01–1.26 0.04 8.59;0.13;41.8

* In McHutchison’s study [19] only patients without ribavirin reduction were included.

** In McHutchison’s study [19] only patients with adequate ribavirin dosage (≥13 mg/kg/die) were included.

Coppola et al.

Coppola et al. BMC Infectious Diseases 2012 12:357   doi:10.1186/1471-2334-12-357

Open Data